148 related articles for article (PubMed ID: 10395037)
1. Estrogen-progestogen therapy for low bone mineral density in primary biliary cirrhosis.
Olsson R; Mattsson LA; Obrant K; Mellström D
Liver; 1999 Jun; 19(3):188-92. PubMed ID: 10395037
[TBL] [Abstract][Full Text] [Related]
2. An open, randomized, controlled study of transdermal hormone replacement therapy on the rate of bone loss in primary biliary cirrhosis.
Ormarsdóttir S; Mallmin H; Naessén T; Petrén-Mallmin M; Broomé U; Hultcrantz R; Lööf L
J Intern Med; 2004 Jul; 256(1):63-9. PubMed ID: 15189367
[TBL] [Abstract][Full Text] [Related]
3. Osteoporosis in primary biliary cirrhosis revisited.
Newton J; Francis R; Prince M; James O; Bassendine M; Rawlings D; Jones D
Gut; 2001 Aug; 49(2):282-7. PubMed ID: 11454807
[TBL] [Abstract][Full Text] [Related]
4. Peripheral quantitative computed tomography (pQCT) is useful for monitoring bone mineral density of the patients who receive hormone replacement therapy.
Sawada K; Morishige K; Ohmichi M; Nishio Y; Yamamoto T; Hayakawa J; Mabuchi S; Isobe A; Sasaki H; Sakata M; Tasaka K; Murata Y
Maturitas; 2007 Apr; 56(4):343-9. PubMed ID: 17010541
[TBL] [Abstract][Full Text] [Related]
5. Primary biliary cirrhosis is not an additional risk factor for bone loss in women receiving regular calcium and vitamin D supplementation: a controlled longitudinal study.
Benetti A; Crosignani A; Varenna M; Giussani CS; Allocca M; Zuin M; Podda M; Battezzati PM
J Clin Gastroenterol; 2008 Mar; 42(3):306-11. PubMed ID: 18223492
[TBL] [Abstract][Full Text] [Related]
6. Longitudinal bone loss in postmenopausal women with primary biliary cirrhosis and well-preserved liver function.
Ormarsdóttir S; Ljunggren O; Mallmin H; Olsson R; Prytz H; Lööf L
J Intern Med; 2002 Dec; 252(6):537-41. PubMed ID: 12472915
[TBL] [Abstract][Full Text] [Related]
7. Comparison of the effects of raloxifene and low-dose hormone replacement therapy on bone mineral density and bone turnover in the treatment of postmenopausal osteoporosis.
Dane C; Dane B; Cetin A; Erginbas M
Gynecol Endocrinol; 2007 Jul; 23(7):398-403. PubMed ID: 17701771
[TBL] [Abstract][Full Text] [Related]
8. Primary biliary cirrhosis and osteoporosis: a case-control study.
Mounach A; Ouzzif Z; Wariaghli G; Achemlal L; Benbaghdadi I; Aouragh A; Bezza A; El Maghraoui A
J Bone Miner Metab; 2008; 26(4):379-84. PubMed ID: 18600405
[TBL] [Abstract][Full Text] [Related]
9. Osteopenia in primary biliary cirrhosis and cirrhosis of the liver in women, evaluated by dual-energy X-ray absorptiometry.
Shiomi S; Kuroki T; Masaki K; Takeda T; Nishiguchi S; Nakajima S; Seki S; Kobayashi K; Okamura T; Ochi H
J Gastroenterol; 1994 Oct; 29(5):605-9. PubMed ID: 8000509
[TBL] [Abstract][Full Text] [Related]
10. Sodium fluoride prevents bone loss in primary biliary cirrhosis.
Guañabens N; Parés A; del Rio L; Roca M; Gómez R; Muñoz J; Rodés J
J Hepatol; 1992 Jul; 15(3):345-9. PubMed ID: 1447501
[TBL] [Abstract][Full Text] [Related]
11. Does vitamin D strengthen the increase in femoral neck BMD in osteoporotic women treated with estrogen?
Tuppurainen MT; Komulainen M; Kröger H; Honkanen R; Jurvelin J; Puntila E; Heikkinen AM; Alhava E; Saarikoski S
Osteoporos Int; 1998; 8(1):32-8. PubMed ID: 9692075
[TBL] [Abstract][Full Text] [Related]
12. [Effects of estrogen therapy on bone mass in postmenopausal women with osteopenia].
Insua A; Negri A; Zanchetta JR
Medicina (B Aires); 1995; 55(5 Pt 1):408-14. PubMed ID: 8728770
[TBL] [Abstract][Full Text] [Related]
13. Safety and efficacy of estrogen therapy in preventing bone loss in primary biliary cirrhosis.
Menon KV; Angulo P; Boe GM; Lindor KD
Am J Gastroenterol; 2003 Apr; 98(4):889-92. PubMed ID: 12738473
[TBL] [Abstract][Full Text] [Related]
14. Effects on bone mass after eight years of hormonal replacement therapy.
Eiken P; Nielsen SP; Kolthoff N
Br J Obstet Gynaecol; 1997 Jun; 104(6):702-7. PubMed ID: 9197874
[TBL] [Abstract][Full Text] [Related]
15. Bone loss in primary biliary cirrhosis: absence of association with severity of liver disease.
Le Gars L; Grandpierre C; Chazouillères O; Berenbaum F; Poupon R
Joint Bone Spine; 2002 Mar; 69(2):195-200. PubMed ID: 12027312
[TBL] [Abstract][Full Text] [Related]
16. Randomized trial comparing low-dose hormone replacement therapy and HRT plus 1alpha-OH-vitamin D3 (alfacalcidol) for treatment of postmenopausal bone loss.
Mizunuma H; Shiraki M; Shintani M; Gorai I; Makita K; Itoga S; Mochizuki Y; Mogi H; Iwaoki Y; Kosha S; Yasui T; Ishihara O; Kurabayashi T; Kasuga Y; Hayashi K
J Bone Miner Metab; 2006; 24(1):11-5. PubMed ID: 16369892
[TBL] [Abstract][Full Text] [Related]
17. [Decreased bone mineral density and gene polymorphism in primary biliary cirrhosis].
Lakatos PL; Bajnok E; Tornai I; Folhoffer A; Horváth A; Lakatos P; Szalay F
Orv Hetil; 2004 Feb; 145(7):331-6. PubMed ID: 15049048
[TBL] [Abstract][Full Text] [Related]
18. Non-invasive assessment of bone density in primary biliary cirrhosis.
Pereira SP; Bray GP; Pitt PI; Li F; Moniz C; Williams R
Eur J Gastroenterol Hepatol; 1999 Mar; 11(3):323-8. PubMed ID: 10333207
[TBL] [Abstract][Full Text] [Related]
19. The benefit of hormone replacement therapy on bone mass is greater at the vertebral body than posterior processes or proximal femur.
Duan Y; Tabensky A; DeLuca V; Seeman E
Bone; 1997 Nov; 21(5):447-51. PubMed ID: 9356739
[TBL] [Abstract][Full Text] [Related]
20. Effect of 10 years' hormone replacement therapy on bone mineral content in postmenopausal women.
Eiken P; Kolthoff N; Nielsen SP
Bone; 1996 Nov; 19(5 Suppl):191S-193S. PubMed ID: 8922661
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
